$0.52 EPS Expected for Xcel Energy Inc. (XEL); Progenics Pharmaceuticals Has 1.22 Sentiment

April 19, 2018 - By Richard Conner

Progenics Pharmaceuticals Inc (PGNX) investors sentiment increased to 1.22 in 2017 Q4. It’s up 0.11, from 1.11 in 2017Q3. The ratio is more positive, as 62 active investment managers started new and increased equity positions, while 51 cut down and sold equity positions in Progenics Pharmaceuticals Inc. The active investment managers in our database now own: 56.89 million shares, down from 58.90 million shares in 2017Q3. Also, the number of active investment managers holding Progenics Pharmaceuticals Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 40 Increased: 40 New Position: 22.

Analysts expect Xcel Energy Inc. (NASDAQ:XEL) to report $0.52 EPS on April, 26 before the open.They anticipate $0.05 EPS change or 10.64% from last quarter’s $0.47 EPS. XEL’s profit would be $264.51 million giving it 21.79 P/E if the $0.52 EPS is correct. After having $0.42 EPS previously, Xcel Energy Inc.’s analysts see 23.81% EPS growth. The stock decreased 0.64% or $0.29 during the last trading session, reaching $45.32. About 1.80 million shares traded. Xcel Energy Inc. (NASDAQ:XEL) has risen 0.76% since April 19, 2017 and is uptrending. It has underperformed by 10.79% the S&P500.

Ardsley Advisory Partners holds 1.32% of its portfolio in Progenics Pharmaceuticals, Inc. for 1.83 million shares. Phocas Financial Corp. owns 1.44 million shares or 0.72% of their US portfolio. Moreover, Rice Hall James & Associates Llc has 0.32% invested in the company for 1.38 million shares. The New York-based Sio Capital Management Llc has invested 0.28% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 2.21 million shares.

The stock decreased 2.18% or $0.16 during the last trading session, reaching $7.17. About 775,003 shares traded. Progenics Pharmaceuticals, Inc. (PGNX) has declined 32.66% since April 19, 2017 and is downtrending. It has underperformed by 44.21% the S&P500.

Ratings analysis reveals 100% of Progenics Pharm’s analysts are positive. Out of 2 Wall Street analysts rating Progenics Pharm, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. PGNX was included in 2 notes of analysts from October 27, 2016. The rating was initiated by Aegis Capital on Thursday, October 27 with “Buy”. The rating was upgraded by Needham to “Strong Buy” on Monday, February 6.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $520.99 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on May, 3. They expect $-0.23 EPS, 0.00% or $0.00 from last year’s $-0.23 per share. After $-0.21 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 9.52% negative EPS growth.

Xcel Energy Inc., through its subsidiaries, engages primarily in the generation, purchase, transmission, distribution, and sale of electricity in the United States. The company has market cap of $23.05 billion. It operates through Regulated Electric Utility, Regulated Natural Gas Utility, and All Other divisions. It has a 20.14 P/E ratio. The firm generates electricity through coal, nuclear, natural gas, hydroelectric, solar, biomass, oil and refuse, and wind energy sources.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.16, from 1.09 in 2017Q3. It increased, as 30 investors sold Xcel Energy Inc. shares while 174 reduced holdings. 64 funds opened positions while 192 raised stakes. 367.42 million shares or 0.08% more from 367.12 million shares in 2017Q3 were reported. Pggm Invs holds 0.26% of its portfolio in Xcel Energy Inc. (NASDAQ:XEL) for 954,700 shares. Blackrock Incorporated owns 42.69M shares for 0.1% of their portfolio. Dimensional Fund Advsr L P has invested 0.02% in Xcel Energy Inc. (NASDAQ:XEL). Harbour Inv Mgmt Ltd Llc stated it has 6,147 shares or 0.21% of all its holdings. Shell Asset has invested 0.13% in Xcel Energy Inc. (NASDAQ:XEL). Tealwood Asset Mgmt has invested 0.08% of its portfolio in Xcel Energy Inc. (NASDAQ:XEL). Opus Inv Mgmt has invested 1.03% of its portfolio in Xcel Energy Inc. (NASDAQ:XEL). Carlson Mngmt reported 5,138 shares or 0.07% of all its holdings. Central Financial Bank & owns 1,918 shares. Strs Ohio accumulated 74,571 shares. Sei owns 369,175 shares for 0.06% of their portfolio. Jpmorgan Chase Company owns 0.34% invested in Xcel Energy Inc. (NASDAQ:XEL) for 33.56M shares. Private Advisor Gru Limited owns 6,522 shares. Windsor Mgmt Ltd Liability Com owns 0.29% invested in Xcel Energy Inc. (NASDAQ:XEL) for 12,938 shares. Omers Administration Corporation holds 177,000 shares or 0.09% of its portfolio.

By1 Richard Conner